BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 540 filers reported holding BIO-TECHNE CORP in Q2 2022. The put-call ratio across all filers is 0.42 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $1,417,769 | +18.5% | 17,106 | +306.2% | 1.14% | +6.9% |
| Q3 2022 | $1,196,000 | -16.7% | 4,211 | +1.7% | 1.06% | +0.4% |
| Q2 2022 | $1,436,000 | -18.2% | 4,142 | +2.1% | 1.06% | -5.4% |
| Q1 2022 | $1,756,000 | -6.3% | 4,056 | +12.0% | 1.12% | -0.6% |
| Q4 2021 | $1,874,000 | +17.9% | 3,623 | +10.4% | 1.13% | +8.5% |
| Q3 2021 | $1,590,000 | +15.5% | 3,281 | +7.3% | 1.04% | +85.7% |
| Q2 2021 | $1,377,000 | +21.8% | 3,059 | +3.3% | 0.56% | +22.5% |
| Q1 2021 | $1,131,000 | +8.1% | 2,962 | -10.1% | 0.46% | -0.4% |
| Q4 2020 | $1,046,000 | +30.6% | 3,295 | +1.9% | 0.46% | +38.7% |
| Q3 2020 | $801,000 | +1.3% | 3,234 | +7.9% | 0.33% | -13.8% |
| Q2 2020 | $791,000 | +67.2% | 2,997 | +20.3% | 0.38% | +36.7% |
| Q1 2020 | $473,000 | -11.1% | 2,492 | +2.8% | 0.28% | +15.6% |
| Q4 2019 | $532,000 | +20.1% | 2,424 | +7.2% | 0.24% | +13.6% |
| Q3 2019 | $443,000 | -69.6% | 2,262 | -67.6% | 0.21% | -8.2% |
| Q2 2019 | $1,456,000 | +211.1% | 6,984 | +196.3% | 0.23% | +4.0% |
| Q1 2019 | $468,000 | +34.9% | 2,357 | -1.8% | 0.22% | +23.8% |
| Q4 2018 | $347,000 | -18.5% | 2,401 | +15.2% | 0.18% | -1.1% |
| Q3 2018 | $426,000 | – | 2,085 | – | 0.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ownership Capital B.V. | 972,263 | $308,742,000 | 4.35% |
| Sandhill Capital Partners LLC | 138,864 | $44,096,000 | 4.03% |
| STONE RUN CAPITAL, LLC | 27,350 | $8,685,000 | 3.45% |
| DF DENT & CO INC | 925,823 | $293,995,000 | 3.42% |
| Brown Capital Management | 1,498,233 | $475,764,000 | 3.29% |
| MAIRS & POWER INC | 848,081 | $269,308,000 | 2.99% |
| Summit Creek Advisors LLC | 64,179 | $20,380,000 | 2.62% |
| GENEVA CAPITAL MANAGEMENT LLC | 402,958 | $127,959,000 | 2.17% |
| Aristotle Atlantic Partners, LLC | 86,993 | $27,625,000 | 2.13% |
| CROWN ADVISORS MANAGEMENT, INC. | 8,000 | $2,540,000 | 1.82% |